The Current Role of Circulating Tumor Cells in the Diagnosis and Management of Bone Metastases in Advanced Prostate Cancer

• Haas GP , DelongchampsN, BrawleyOW, WangCY, de la RozaG. The worldwide epidemiology of prostate cancer: perspectives from autopsy studies.Can. J. Urol.15(1), 3866–3871 (2008).
   PubMed Web of Science ®Google Scholar
• Ross RK , BernsteinL, LoboRAet al. 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 339(8798), 887–889 (1992).
   PubMed Web of Science ®Google Scholar
• Stamey TA , YangN, HayAR, McNealJE, FreihaFS, RedwineE. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.N. Engl. J. Med.317(15), 909–916 (1987).
   PubMed Web of Science ®Google Scholar
• Constantinou J , FeneleyMR. PSA testing: an evolving relationship with prostate cancer screening.Prostate Cancer Prostatic Dis.9(1), 6–13 (2006).
   PubMed Web of Science ®Google Scholar
• Etzioni R , FeuerE. Studies of prostate-cancer mortality: caution advised.Lancet Oncol.9(5), 407–409 (2008).
   PubMed Web of Science ®Google Scholar
• Collette L , BurzykowskiT, CarrollKJ, NewlingD, MorrisT, SchroderFH. Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals.J. Clin. Oncol.23(25), 6139–6148 (2005).
   PubMed Web of Science ®Google Scholar
• Scher HI , WarrenM, HellerG. The association between measures of progression and survival in castrate-metastatic prostate cancer.Clin. Cancer Res.13(5), 1488–1492 (2007).
   PubMed Web of Science ®Google Scholar
• Leman ES , GetzenbergRH. Biomarkers for prostate cancer.J. Cell. Biochem.108(1), 3–9 (2009).
   PubMed Web of Science ®Google Scholar
• Thompson IM , PaulerDK, GoodmanPJet al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per mililiter. N. Engl. J. Med. 350(22), 2239–2246 (2004); erratum: 351(14), 1470 (2004).
   PubMed Web of Science ®Google Scholar
• Bunting PS . A guide to the interpretation of serum prostate specific antigen levels.Clin. Biochem.28(3), 221–241 (1995).
   PubMed Web of Science ®Google Scholar
• Loeb S , CataonaWJ. Prostate-specific antigen in clinical practice.Cancer Lett.249(1), 30–39 (2007).
   PubMed Web of Science ®Google Scholar
• Carter HB , PearsonJD, MetterEJet al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267(16), 2215–2220 (1992).
   PubMed Web of Science ®Google Scholar
• Lembessis P , MsaouelP, HalapasAet al. Combined androgen therapy blockade can convert RT-PCR detection of prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) transcripts from positive to negative in the peripheral blood of patients with clinically localized prostate cancer and increase biochemical failure-free survival after curative therapy. Clin. Chem. Lab. Med. 45(11), 1488–1494 (2007).
   PubMed Web of Science ®Google Scholar
• Saad F , PerezJ, CookR, SegalS. Evaluation of prostate-specific antigen kinetics during zoledronic acid therapy for bone metastases in patients with castration-resistant prostate cancer. Presented at:AUA Annual Meeting. Washington DC, USA, 14–19 May 2011 (Abstract 717).
   Google Scholar
• Bubendorf L , SchopferA, WagnerUet al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum. Pathol. 31(5), 578–583 (2000).
   PubMed Web of Science ®Google Scholar
• Noguchi M , KikuchiH, IshibashiM, NodaS. Percentage of the positive area of bone metastasis is an independent predictor of disease death in advanced prostate cancer.Br. J. Cancer88(2), 195–201 (2003).
   PubMed Web of Science ®Google Scholar
• Parker C . Overall survival benefit of radium-223 chloride (alpharadin) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer: a Phase III randomized trial (ALSYMPCA). Presented at:ECCO-ESMO Stockholm, Sweden, 23–27 September 2011 (Abstract 1LBA).
   Google Scholar
• Smith MR , EgerdieB, HernandezNet al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N. Engl. J. Med. 361(8), 745–755 (2009).
   PubMed Web of Science ®Google Scholar
• Ryan CJ , ShahS, EfstathiouEet al. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin. Cancer Res. 17(14), 4854–4861 (2011).
   PubMed Web of Science ®Google Scholar
• Saad F . Clinical benefit of zoledronic acid for the prevention of skeletal complications in advanced prostate cancer.Clin. Prostate Cancer4(1), 31–37 (2005).
   PubMedGoogle Scholar
• Smith MR , KabbinavarF, SaadFet al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J. Clin. Oncol. 23(13), 2918–2925 (2005).
   PubMed Web of Science ®Google Scholar
• Sutcliffe P , HummelS, SimpsonEet al. Use of classical and novel biomarkers as prognostic risk factors for localised prostate cancer: a systematic review. Health Technol. Assess. 15(5), iii, xi–xiii 1–219 (2009).
   Google Scholar
• Coleman RE , MajorP, LiptonAet al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J. Clin. Oncol. 23(22), 4925–4935 (2005).
   PubMed Web of Science ®Google Scholar
• Cook RJ , ColemanR, BrownJet al. Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin. Cancer Res. 12(11 Pt 1), 3361–3367 (2006).
   PubMed Web of Science ®Google Scholar
• Saad F , LiptonA, CookR, ChenYM, SmithM, ColemanR. Pathologic fractures correlate with reduced survival in patients with malignant bone disease.Cancer110(8), 1860–1867 (2007).
   PubMed Web of Science ®Google Scholar
• Coleman RE . Metastatic bone disease: clinical features, pathophysiology, and treatment strategies.Cancer Treat. Rev.27(3), 165–176 (2001).
   PubMed Web of Science ®Google Scholar
• Weinfurt KP , LiY, CastelLDet al. The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann. Oncol. 16(4), 579–584 (2005).
   PubMed Web of Science ®Google Scholar
• Demers LM , CostaL, LiptonA. Biochemical markers and skeletal metastases.Cancer88(Suppl. 12), 2919–2926 (2000).
   PubMedGoogle Scholar
• Kingsley LA , FournierPG, ChirgwinJM, GuiseTA. Molecular biology of bone metastasis.Mol. Cancer Ther.6(10), 2609–2617 (2007).
   PubMed Web of Science ®Google Scholar
• Thayer S , CookeJ, KauraS. A retrospective database analysis to assess the impact of zoledronic acid (ZOL) on skeletal-related events (SREs) in solid tumor cancer and multiple myeloma (MM) patients (pts). Presented at:2009 ASCO Annual Meeting Orlando, FL, USA, 29 May–2 June 2009 (Abstract 9518).
   Google Scholar
• Saad F , GleasonDM, MurrayRet al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J. Natl Cancer Inst. 96(11), 879–882 (2004).
   PubMed Web of Science ®Google Scholar
• Coleman RE . Skeletal complications of malignancy.Cancer80(8 Suppl.), 1588–1594 (1997).
   PubMed Web of Science ®Google Scholar
• Fizazi K , CarducciMA, SmithMRet al. A randomized Phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer. J. Clin. Oncol. 28(Suppl. 18), Abstract LBA4507 (2010).
   Web of Science ®Google Scholar
• Pantel K , Alix-PanabieresC. Circulating tumour cells in cancer patients: challenges and perspectives.Trends Mol. Med.16(9), 398–406 (2010).
   PubMed Web of Science ®Google Scholar
• Ashworth TR . A case of cancer in which cells similar to those in the tumours were seen in the blood after death.Aust. Med. J.14, 146 (1869).
   Google Scholar
• Hugo H , AcklandML, BlickTet al. Epithelial–mesenchymal and mesenchymal–epithelial transitions in carcinoma progression. J. Cell. Physiol. 213(2), 374–383 (2007).
   PubMed Web of Science ®Google Scholar
• Thiery JP . Epithelial–mesenchymal transitions in tumour progression.Nat. Rev. Cancer2(6), 442–454 (2002).
   PubMed Web of Science ®Google Scholar
• Steeg PS . Metastasis suppressors alter the signal transduction of cancer cells.Nat. Rev. Cancer3(1), 55–63 (2003).
   PubMed Web of Science ®Google Scholar
• Lafrenie R , ShaughnessySG, OrrFW. Cancer cell interactions with injured or activated endothelium.Cancer Metastasis Rev.11(3–4), 377–388 (1992).
   PubMed Web of Science ®Google Scholar
• Riethdorf S , FritscheH, MullerVet al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin. Cancer Res. 13(3), 920–928 (2007).
   PubMed Web of Science ®Google Scholar
• Dotan E , CohenSJ, AlpaughKR, MeropolNJ. Circulating tumor cells: evolving evidence and future challenges.Oncologist14(11), 1070–1082 (2009).
   PubMed Web of Science ®Google Scholar
• Stott SL , LeeRJ, NagrathSet al. Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci. Transl Med. 2(25), 25ra23 (2010).
   PubMed Web of Science ®Google Scholar
• Pelkey TJ , FriersonHFJr, BrunsDE. Molecular and immunological detection of circulating tumor cells and micrometastases from solid tumors.Clin. Chem.42(9), 1369–1381 (1996).
   PubMed Web of Science ®Google Scholar
• Davis JW , NakanishiH, KumarVet al. Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer. J. Urol. 179(6), 2187–2191 (2008).
   PubMed Web of Science ®Google Scholar
• Kollerman J , WeikertS, SchostakMet al. Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment. J. Clin. Oncol. 26(30), 4928–4933 (2008).
   PubMed Web of Science ®Google Scholar
• Weckermann D , PolzerB, RaggTet al. Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer. J. Clin. Oncol. 27(10), 1549–1556 (2009).
   PubMed Web of Science ®Google Scholar
• Alix-Panabieres C , VendrellJP, PelleOet al. Detection and characterization of putative metastatic precursor cells in cancer patients. Clin. Chem. 53(3), 537–539 (2007).
   PubMed Web of Science ®Google Scholar
• Allard WJ , MateraJ, MillerMCet al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin. Cancer Res. 10(20), 6897–6904 (2004).
   PubMed Web of Science ®Google Scholar
• Mani SA , GuoW, LiaoMJet al. The epithelial–mesenchymal transition generates cells with properties of stem cells. Cell 133(4), 704–715 (2008).
   PubMed Web of Science ®Google Scholar
• Alix-Panabieres C , SchwarzenbackH, PantelK. Circulating tumor cells and circulating tumor DNA.Annu. Rev. Med.63, 199–215 (2012).
   PubMed Web of Science ®Google Scholar
• Eschwege P , MoutereauS, DroupySet al. Prognostic value of prostate circulating cells detection in prostate cancer patients: a prospective study. Br. J. Cancer 100(4), 608–610 (2009).
   PubMed Web of Science ®Google Scholar
• de Bono JS , ScherHI, MontgomeryRBet al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 14(19), 6302–6309 (2008).
   PubMed Web of Science ®Google Scholar
• Scher HI , JiaX, de BonoJSet al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol. 10(3), 233–239 (2009).
   PubMed Web of Science ®Google Scholar
• Olmos D , ArkenauHT, AngJEet al. Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. Ann. Oncol. 20(1), 27–33 (2009).
   PubMed Web of Science ®Google Scholar
• Danila DC , HellerG, GignacGAet al. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin. Cancer Res. 13(23), 7053–7058 (2007).
   PubMed Web of Science ®Google Scholar
• Reid AH , AttardG, DanilaDCet al. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J. Clin. Oncol. 28(9), 1489–1495 (2010).
   PubMed Web of Science ®Google Scholar
• Scher HI , HellerG, MolinaAet al. Evaluation of circulating tumor cell (CTC) enumeration as an efficacy response biomarker of overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC): planned final analysis of COU-AA-301, a randomized double-blind, placebo-controlled Phase III study of abiraterone acetate (AA) plus low-dose prednisone (P) post docetaxel. J. Clin. Oncol. 29(Suppl.), Abstract LBA4517 (2011).
   Google Scholar
• Aft R , NaughtonM, TrinkausKet al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, Phase 2 trial. Lancet Oncol. 11(5), 421–428 (2010).
   PubMed Web of Science ®Google Scholar
• Saad F , EasthamJ. Zoledronic acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer.Urology76(5), 1175–1181 (2010).
   PubMed Web of Science ®Google Scholar
• Kraan J , SleijferS, StrijbosMHet al. External quality assurance of circulating tumor cell enumeration using the CellSearch® system: a feasibility study. Cytometry B Clin. Cytom. 80(2), 112–118 (2011).
   PubMed Web of Science ®Google Scholar
• Doyen J , Alix-PanabieresC, HofmanPet al. Circulating tumor cells in prostate cancer: a potential surrogate marker of survival. Crit. Rev. Oncol. Hematol. 81(3), 241–256 (2011) (Epub ahead of print).
   PubMed Web of Science ®Google Scholar

Websites

• GLOBOCAN. Age standardized incidence rates for prostate cancer (2008). http://globocan.iarc.fr/factsheets/cancers/prostate.asp
   Google Scholar
• US FDA. FDA public workshop on clinical trial endpoints in prostate cancer (2004). www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/CancerDrugs/ucm095039.pdf
   Google Scholar